1[1]Menzies D,Ellis H.Intra-abdominal adhesions and their prevention by topical tissue plasminogen activator[J].J R Soc Med.1989,82(9):534-535.
2[2]Almdahl SM,Burhol PG.Peritoneal adhesions:causes and prevention[J].Dig Dis.1990; 8(1):37-44.
3[3]Vipond MN,Whawell SA,Thompson JN,et al.Peritoneal fibrinolytic activity and intra-abdominal adhesions[J].Lancet.1990,335(8698):1120-1122.
4[4]Wun TC,Capuano A.Spontaneous fibrinolysis in whole human plasma.Identification of tissue activator-related protein as the major plasminogen activator causing sponta neous activity in vitro[J].J Biol Chem.1985; 260(8):5061-5066.
5[5]Thompson JN,Paterson-Brown S,Harboume T,et al.Recluced human peritoneal plasminogen activating activity:possible mechanism of adhesion formation[J].Br J Surg.1989,76(4):382-384.
6[6]Miller GL,Graziano C J,Lim RC.Human monocyte plasminogen activator production:correlation to altered M phiT lymphocyte interaction[J].J Immunol.1982; 128(5):2194-2200.
7[7]Menzies D,Ellis H.The role of plasminogen activator in adhesion prevention[J].Surg Gynecol Obstet.1991; 172(5):362-366.
9[10]van Hinsbergh VW,van den Berg EA,Fiers W,et al.Tumor necrosis factor induces the production of urokinasetype plasminogen activator by human endothelial ceLls[J].Blood.1990; 75(10):1991-1998.
10[11]Saba AA,Godziachvili V,Mavani AK,et al.Serum levels of interleukin 1 and tumor necrosis factor alpha correlate with peritoneal adhesion grades in humans after major abdominal surgery[J].Am Surg.1998; 64(8):734-737.
2Bosteels J, Kasius J, Weyers S, et al. Treating suspected uterine cavity abnormalities by hysteroscopy to improve reproduc- tive outcome in women with unexplained infertility or prior to IUI, IVF, or ICSI. Gynecol Surg, 2013, 10(3):165-7.
3Chen Y, Chang Y, Yao S. Role of angiogenesis in endometrial repair of patients with severe intrauterine adhesion. Int J Clin Exp Pathol, 2013, 6(7): 1343-50.
4Johary J, Xue M, Zhu X, et al. The efficacy of estrogen therapy in patients with intrauterine adhesions: a systematic review. J Minim Invasive Gynecol, 2014, 21(1):44-54.
5Deans R, Abbott J. Review of intrauterine adhesions. J Minim Invasive Gynecol, 2010, 17(5):555-69.
6March CM, Isreal R, March AD. Hysteroscopic management of intrauterine adhesions. Am J Obstet Gynecol, 1978, 130 (6):653-7.
7Myers EM, Hurst BS. Comprehensive management of severe Asherman syndrome and amenorrhea. Fertil Steril, 2012, 97 (1):160-4.
8Comninos AC, Zourlas PA. Treatment of uterine adhesions (Asherman's syndrome). Am J Obstet Gynecol, 1996, 105 (6):862.
9Guida M, Acunzo G, Di Spiezio Sardo A, et al. Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Hum Reprod, 2004, 19(6):1461-4.
10Mettler L, Sammur W, Schollmeyer T, et al. Cross-linked sodium hyaluronate, an anti-adhesion barrier gel in gynaecological endoscopic surgery. Minim Invasive Ther Allied Technol, 2013, 22(5):260-5.
